Nuo Therapeutics, INC
Market Movers (8-K)
OQB
Nuo Therapeutics announced strong first quarter 2026 financial results, with total revenues soaring 169% year-over-year, driven by significant growth in its Aurix product line.
Better than expected
Capital raise
OQB
Nuo Therapeutics, Inc. has entered into a Loan and Security Agreement for up to $1.6 million, accompanied by significant warrant issuances and high interest rates, to fund general working capital.
Worse than expected
Capital raise
OQB
Nuo Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders, electing four directors, ratifying MaloneBailey LLP as auditor, and approving executive compensation on an advisory basis.
OQB
Nuo Therapeutics, Inc. announced salary increases for its CEO/CFO and CSO/COO, citing improved business conditions, and set its 2025 Annual Meeting for December 16, 2025.
Better than expected
OQB
Nuo Therapeutics and Smith+Nephew have amended their distribution agreement to include an interim sales agency arrangement for Nuo Aurix branded products.
OQB
Nuo Therapeutics has successfully completed a private placement, raising $849,125 through the sale of common stock to accredited investors.
Capital raise
Quarterly Earnings (10-Q)
OQB
Nuo Therapeutics reports a significant revenue increase in Q1 2026 driven by product sales and distribution fees, though the company continues to face substantial doubt regarding its ability to continue as a going concern.
Capital raise
Worse than expected
OQB
Nuo Therapeutics reported a significant increase in Q3 2025 revenue driven by product sales and a new distribution agreement with Smith+Nephew, yet continues to face substantial doubt about its ability to continue as a going concern.
Capital raise
Better than expected
OQB
10-Q: Nuo Therapeutics Boosts Revenue with Smith & Nephew Deal, Raises Capital Amidst Going Concern Doubts
Nuo Therapeutics reported significant revenue growth driven by a new distribution agreement with Smith & Nephew and an interim sales agency, while also completing a private placement to address liquidity concerns and ongoing losses.
Worse than expected
Capital raise
OQB
Nuo Therapeutics saw revenue growth in Q1 2025 and entered a distribution agreement with Smith+Nephew, but faces going concern challenges.
Capital raise
Worse than expected
OQB
Nuo Therapeutics saw a significant increase in product revenue in Q3 2024 compared to Q3 2023, but continues to operate with a substantial accumulated deficit and going concern uncertainty.
Better than expected
Capital raise
OQB
10-Q: Nuo Therapeutics Reports Increased Revenue in Second Quarter 2024, Faces Going Concern Uncertainty
Nuo Therapeutics saw a significant increase in product revenue in the second quarter of 2024 compared to 2023, but continues to face challenges regarding its ability to continue as a going concern.
Better than expected
Capital raise
Annual Reports (10-K)
OQB
Nuo Therapeutics, a medical device company, announced significant revenue growth in 2025 driven by its Aurix product and a new distribution agreement with Smith+Nephew, alongside securing new debt financing, despite ongoing net losses and a going concern warning.
Worse than expected
Capital raise
OQB
Nuo Therapeutics reports increased revenues for 2024 and a new distribution agreement with Smith+Nephew for its Aurix product.
Capital raise
Worse than expected
OQB
Nuo Therapeutics, a regenerative therapies company, reported increased product revenue in 2023 but continues to face financial challenges and going concern uncertainties.
Worse than expected
Capital raise
Insider Trading (Form 4)
OQB
Peter Clausen, CSO/COO of Nuo Therapeutics, Inc., received an option grant for 65,000 shares of common stock.
OQB
Nuo Therapeutics CEO David Emerson reports significant stock transactions, including option exercises and acquisitions, impacting his beneficial ownership.
OQB
Scott M. Pittman, a Director and 10% Owner of Nuo Therapeutics, Inc., reported transactions involving the acquisition and net exercise of stock options.
OQB
Nuo Therapeutics, Inc. Director C. Eric Winzer reports transactions involving common stock and stock options.
OQB
Nuo Therapeutics Director Paul Mintz acquired 30,000 stock options on June 29, 2026, as detailed in a Form 4 filing.
OQB
Nuo Therapeutics CEO and CFO David Jorden acquired 13,245 shares of common stock at a weighted average price of $1.0952.
Proxy Statements (Def-14A)
OQB
NUO THERAPEUTICS, INC. has filed a Definitive Additional Materials proxy statement with the SEC.
OQB
Nuo Therapeutics, Inc. will hold its Annual Meeting to elect directors, ratify auditors, and vote on executive compensation, following a period of financial recovery and capital raises.
Capital raise
Better than expected
Schedule 13D - Activist Investments
OQB
Scott M. Pittman amends Schedule 13D regarding Nuo Therapeutics, detailing loan agreements and warrant issuances.
Capital raise
OQB
SCHEDULE 13D/A: Nuo Therapeutics Secures $200K Loan, Insider Boosts Stake
Nuo Therapeutics, Inc. has secured a $200,000 loan from insider Scott M. Pittman, who increased his beneficial ownership to 11.6% through new warrants.
Capital raise
Schedule 13G - Passive Investments
OQB
Paul Anthony Jacobs has reported beneficial ownership of 6.6% of Nuo Therapeutics, Inc.'s common stock, including exercisable warrants.